- Extensive apoptosis of malignant cells
- Decreased tumor invasiveness and metastasis
- Decreased tumor and endothelial cell proliferation
- Blockade of metastatic bone lesion progression
- Disruption of tumor vasculature
Ultragenyx, together with Kyowa Hakko Kirin and Kyowa Kirin International, on Tuesday unveiled 24-week data from a phase three study of burosumab in adults.
Jim Cramer is bullish on Incyte, Skyworks Solutions, Western Digital, Constellation Brands and more.
This market may be cheaper than it looks, especially if companies can keep delivering on the earnings front, says Jim Cramer.